Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
4.543
-0.047 (-1.02%)
At close: Apr 28, 2026, 4:00 PM EDT
4.320
-0.223 (-4.92%)
After-hours: Apr 28, 2026, 7:17 PM EDT
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
6.28M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 2.98M |
| CollPlant Biotechnologies | 2.37M |
| XTL Biopharmaceuticals | 968.00K |
| Can-Fite BioPharma | 405.00K |
| BioRestorative Therapies | 359.70K |
| Alaunos Therapeutics | 5.00K |
| Ernexa Therapeutics | 1,000.00 |
PPBT News
- 6 weeks ago - Purple Biotech Announces CEO Transition - GlobeNewsWire
- 2 months ago - Purple Biotech Announces Plan to Implement ADS Ratio Change - GlobeNewsWire
- 5 months ago - Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress - GlobeNewsWire
- 5 months ago - Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform - GlobeNewsWire
- 6 months ago - Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification - GlobeNewsWire
- 8 months ago - Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants - GlobeNewsWire
- 8 months ago - Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire